Clinical Development

Phase 3 Clinical Trial(Phase 3)

Large-scale pivotal trials that confirm a drug's efficacy and safety to support regulatory approval.

Usage Examples

Both Phase 3 trials met their primary endpoints.
The Phase 3 program enrolled over 3,000 patients worldwide.
Pivotal Phase 3 data were included in the NDA submission.

What is Phase 3?

Phase 3 clinical trials are large, randomized, controlled studies designed to definitively demonstrate a drug's efficacy and safety in the target patient population. These pivotal trials typically enroll hundreds to thousands of patients across multiple sites.

Phase 3 studies use rigorous methodologies including randomization, blinding, and predefined statistical analysis plans. They evaluate clinically meaningful endpoints and gather comprehensive safety data across diverse patient populations.

Successful Phase 3 results form the foundation of regulatory submissions (NDA, BLA, MAA). Most regulatory agencies require two adequate and well-controlled Phase 3 trials, though accelerated pathways may allow approval based on one trial with compelling results.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 312, 21 CFR 314, ICH E9.

FDAEMAPMDA

When This Matters

Both Phase 3 trials met their primary endpoints.
The Phase 3 program enrolled over 3,000 patients worldwide.
Pivotal Phase 3 data were included in the NDA submission.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

21 CFR 31221 CFR 314ICH E9

Frequently Asked Questions

FDA typically requires substantial evidence from adequate and well-controlled studies, which usually means two trials. This provides independent replication and greater confidence in results. Single pivotal trials may suffice with very robust data.

Phase 3 trials typically take 2-4 years to complete, depending on the indication, endpoints, enrollment challenges, and required follow-up duration.

A pivotal trial is designed to provide the primary evidence of efficacy and safety for regulatory approval. It has predefined endpoints, adequate statistical power, appropriate controls, and rigorous conduct.